Brief: Arch Biopartners Granted Meeting With FDA For Candidate Drug
21/03/2018 12:08
March 21 (Reuters) - Arch Biopartners :
* ARCH BIOPARTNERS GRANTED PRE-IND MEETING WITH FDA FOR
CANDIDATE
DRUG TO PREVENT ACUTE KIDNEY INJURY
* ARCH BIOPARTNERS INC - PRE-IND MEETING WITH U.S. FDA
DIVISION
OF CARDIOVASCULAR AND RENAL PRODUCTS DCRP WILL TAKE PLACE ON
APRIL 18, 2018
* ARCH BIOPARTNERS - SUBMITTED INFORMATION PACKAGE TO FDA
DCRP
CONTAINING QUESTIONS & DRAFT IND APPLICATION CONTENT
* ARCH BIOPARTNERS - MEETING FDA TO REVIEW, CONFIRM KEY
COMPONENTS OF A PLANNED IND APPLICATION FOR METABLOK AS
TREATMENT TO PREVENT ACUTE KIDNEY INJURY
Source text for Eikon: ID:nGNXY58dm
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arch Biopartners
See all newsBrief: Arch Biopartners To Expand Phase Ii Cardiac Surgery-Associated Acute Kidney Injury Trial To The US
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Strengthens Its Position As A Leading Kidney Therapeutics Company With The Acquisition Of A Breakthrough Platform To Develop New Drugs Targeting Chronic Kidney Disease (Ckd)
Brief: Arch Biopartners Closes Non-Brokered Private Placement
Brief: Arch Biopartners Announces Ontario Research Ethics Board Approval To Start Phase II Trial For LSALT Peptide